Incannex Healthcare
IXHL | NASDAQ
$1.93
-$0.04 (-2.03%)
At close: Nov 16, 2026, 4:00 PM ET
$1.93
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Incannex Healthcare Company Profile
Company profile explainedCompany Profile
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Key Executives
| Name | Position |
|---|---|
| Joel Bradley Latham | President, Chief Executive Officer & Executive Director |
| John Michailidis EMBA | Chief Executive Officer of IncannexTM |
| Joseph Swan | Chief Financial Officer, Treasurer & Secretary |
| Lekhram Changoer | Chief Technology Officer |
| Luigi Barbato | Chief Medical Officer |
| Mark Bleackley | Chief Scientific Officer, Head of Programs & Member of the Advisory Board |
| Natalie May | Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | ARS | Filing |
| Oct 28, 2026 | DEFA14A | Filing |
| Oct 28, 2026 | DEF 14A | Filing |
| Sep 25, 2026 | 10-K | Annual Report |
| Sep 09, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 23, 2026 | 8-K | Current Report |
| Jun 25, 2026 | 8-K | Current Report |
Incannex Healthcare
| Country | Australia |
| IPO Date | Mar 2, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Joel Bradley Latham |
Contact Details
Rialto South Tower Level 23 Melbourne,
VIC 2153 Australia
Stock Details
| Ticker Symbol | IXHL |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001873875 |
| CUSIP Number | 45333F208 |
| ISIN Number | US45333F2083 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove IXHL